Performing this approach, we identified two inhibitors showing high affinity for recombinant Bcl-2, Bcl-xL and Mcl-1 proteins and in vitro/in vivo anti-tumoral activity in preclinical cancer models with different histotype. The gene discussed is MCL1; the disease is cancer.